A Moderna statement obtained by The Trends Journal claims Pfizer and BioNTech’s COVID-19 vaccine “infringes patents Moderna filed between 2010 and 2016 covering Moderna’s foundational mRNA technology.”
Moderna filed lawsuits over the claimed infringements last month in the United States District Court for the District of Massachusetts and the Regional Court of Düsseldorf in Germany.
Stéphane Bancel, Moderna’s chief executive officer, said the company filed the lawsuits to “protect the innovative mRNA technology platform that we pioneered, invested billions of dollars in creating, and patented during the decade preceding the COVID-19 pandemic.”
“This foundational platform, which we began building in 2010, along with our patented work on coronaviruses in 2015 and 2016, enabled us to produce a safe and highly effective COVID-19 vaccine in record time after the pandemic struck,” he said. “As we work to combat health challenges moving forward, Moderna is using our mRNA technology platform to develop medicines that could treat and prevent infectious diseases like influenza and HIV, as well as autoimmune and cardiovascular diseases and rare forms of cancer.”
Pfizer said in a written statement to CNN that it was surprised by the litigation given the Pfizer/BioNTech COVID-19 Vaccine was based on BioNTech’s proprietary mRNA technology and developed by both BioNTech and Pfizer.
“We remain confident in our intellectual property supporting the Pfizer/BioNTech vaccine and will vigorously defend against the allegations of the lawsuit,” the statement read.
We have noted that these vaccines, since they were mandated by governments, made these companies an enormous financial windfall and minted new billionaires. (See “PFIZER: DRUG DEALERS ON PARADE” 5 Apr 2022, “JAB KIDS WHO WON’T DIE FROM THE VIRUS: THERE’S NO BUSINESS LIVE VAX BUSINESS” 9 Nov 2021, “PFIZER DRUG LORD PUSHING YEARLY COVID JABS. CALLS THOSE WHO WON’T SWALLOW BULLSHIT, ‘CRIMINALS’” 1 Feb 2022 and “MODERNA EXPECTS TO REAP $18.4 BILLION FROM VACCINE SALES” 2 Mar 2021.)
Noubar Afeyan, Moderna’s chairman and co-founder, Robert Langer, a Massachusetts Institute of Technology professor and Moderna co-founder, and Timothy Springer, a Harvard Medical School professor and an early investor in Moderna. Each now has a net worth of over $3.5 billion.
Vaccine use has slumped in the U.S., but Ashish Jha, the White House COVID-19 coordinator, announced last week that a large majority of Americans “are moving to a point where a single annual COVID shot should provide a high degree of protection all year.”
TREND FORECAST: The COVID War has been a financial windfall for many, and especially for those associated with providing the vaccines that the world sees as the main line of defense against the virus; see, for example:
- “DRUG COMPANIES CASHING IN ON COVID” (11 May 2021)
- “DRUG LORDS’ VAX BOOM BOOMING” (8 Jun 2021)
- “DRUG LORDS VAX MONEY GRAB GETTING BIGGER” (17 Aug 2021)
Moderna sold $5.9 billion of its vaccine in the first quarter of 2022. Moderna maintained its full-year guidance of $21 billion in Covid vaccine sales despite the vaccines having a fraction of the 96 percent efficacy which was sold to the public when they were launched in December 2020.
The Food and Drug Administration and the Centers for Disease Control and Prevention gave approval last month for boosters for the BA.5 subvariant for those 12 years old and up. The approval was granted without any data from clinical trials on humans.
“We don’t know for a fact yet whether we will get to that same level, but that is the goal here. And that is what we believe the evidence that we’ve seen helps point to,” Dr. Peter Marks, who heads the FDA office that reviews vaccines, said.